SURMODICS INC: management transactions · United States · SEC (Form 4)

About SURMODICS INC

Surmodics Inc. is a U.S.-based medical technology and diagnostics specialist listed on the NASDAQ market in the United States. For French-speaking investors, it sits in the more defensive end of healthcare: the company combines proprietary surface technology for medical devices with a second line of business in in vitro diagnostics components. Surmodics is headquartered in Eden Prairie, Minnesota, and also operates in Ireland, giving it a transatlantic manufacturing and commercial footprint. The company emphasizes its leadership in lubricious, hemocompatible, and drug-delivery coatings used by major medical device manufacturers. ([surmodics.com](https://www.surmodics.com/about-surmodics)) Surmodics traces its roots back to 1979, when it was organized as a Minnesota corporation, and it became a public company on the Nasdaq in 1998. Over time, the business evolved from a pure coating technology specialist into a broader medtech platform with interventional products, balloon catheter design and manufacturing capabilities, and contract development and manufacturing services. Management highlights its ability to move products from concept to commercialization through close customer collaboration, often on accelerated timelines. ([sec.gov](https://www.sec.gov/Archives/edgar/data/924717/000120677406002591/surmodics_10k.htm?utm_source=openai)) The company’s operating model is now built around two main pillars. The Medical Device segment covers performance coatings, drug-coated balloons, and product development/manufacturing services for device companies. The In Vitro Diagnostics segment supplies chemical and biological components for immunoassay tests and microarrays. This mix gives Surmodics exposure both to cardiovascular and interventional medtech demand and to the broader diagnostic consumables market. Its competitive position is based less on scale and more on technical differentiation, intellectual property, formulation expertise, and the ability to support customers through the full product development cycle. ([surmodics.com](https://www.surmodics.com/about-surmodics)) In competitive terms, Surmodics is best viewed as a niche enabling technology provider rather than a diversified healthcare manufacturer. Its coatings expertise is the core moat: these technologies are designed to improve device performance and support drug-device combination products. The diagnostics business adds another layer of recurring, ingredient-like revenue potential. However, the company remains dependent on a relatively concentrated set of product programs, customer adoption, regulatory execution, and successful commercialization of proprietary platforms. ([surmodics.com](https://www.surmodics.com/about-surmodics)) Recent news has been dominated by the proposed acquisition by GTCR, announced in May 2024. In 2025, Surmodics said the transaction was still subject to litigation with the FTC, which moved to block the deal in federal court. The company also continued to report quarterly results and flagged exposure to tariffs and supply-chain inputs, while discussing revenue from SurVeil DCB and other product lines. For investors, this makes Surmodics a specialized healthcare name with an important M&A overhang and a business mix centered on high-value medical coatings and diagnostic components. ([surmodics.gcs-web.com](https://surmodics.gcs-web.com/static-files/d4fe6fb7-3530-475b-a620-a660fe212c4b))